PCSK9 Inhibitors Linked to Better Survival in Some Cancer Patients on Immunotherapy
A groundbreaking matched-cohort study, recently presented at a major oncology conference, reveals that PCSK9 Inhibitors, typically prescribed for high cholesterol, significantly improve survival in certain cancer patients undergoing treatment with Immune Checkpoint Inhibitors (ICIs). This unexpected synergy suggests a novel pathway to enhance the efficacy of immunotherapy, potentially altering treatment paradigms for difficult-to-treat cancers.

















